278
On 25 October 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 405. The active ingredient is genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM) for treatment of renal cell carcinoma.